Multiple sclerosis and infections;Multiple Sklerose und Infektionskrankheiten

Aktuelle Neurologie

Volumn 38, Issue 7, 2011, Pages 339-350

  Winkelmann, A ^a   Lobermann M ^a   Reisinger, E C ^a   Zettl, U K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

disease modifying treatments; infections; multiple sclerosis; vaccinations

Indexed keywords

DIPHTHERIA VACCINE; YELLOW FEVER VACCINE;

ARTICLE; DIPHTHERIA; HUMAN; IMMUNOMODULATION; INFECTION; MULTIPLE SCLEROSIS; PROPHYLAXIS; TETANUS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VACCINATION; YELLOW FEVER;

EID: 81555213406     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0031-1291296     Document Type: Article

References (122)

1. Hauser S L, Oksenberg J R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron: 2006; 52 61 76 (Pubitemid 44466355)
2. Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 2011;[Epub].
3. Mix E, Meyer-Rienecker H, Hartung H P et al. Animal models of multiple sclerosis potentials and limitations. Prog Neurobiol: 2010; 92 386 404
4. Baranzini S E, Mudge J, van Velkinburgh J C et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature: 2010; 464 1351 1356
5. Dyment D A, Yee I M, Ebers G C et al. Canadian Collaborative Study G. Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry: 2006; 77 258 259 (Pubitemid 43220856)
6. Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature: 2011; 476 214 219
7. Oksenberg J R, Baranzini S E, Sawcer S et al. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet: 2008; 9 516 526 (Pubitemid 351861542)
8. Wingerchuk D M. Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J Med: 2011; 78 221 230
9. Kakalacheva K, Lunemann J D. Environmental triggers of multiple sclerosis. FEBS Lett. 2011;[Epub].
10. Ascherio A, Munger K L, Simon K C. Vitamin D and multiple sclerosis. Lancet Neurol: 2010; 9 599 612
11. Gardener H, Munger K L, Chitnis T et al. Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology: 2009; 20 611 618
12. Banwell B, Bar-Or A, Arnold D L et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol: 2011; 10 436 445
13. Zettl U K, Stuve O, Patejdl R. Immune-mediated CNS diseases: A review on nosological classification and clinical features. Autoimmun Rev: 2011;[Epub].
14. Kamm C, Zettl U K. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev. 2011;[Epub].
15. Lbermann M, Winkelmann A, Reisinger E C et al. Impfen und Multiple Sklerose. Nervenarzt: 2010; 81 181 193
16. Stuve O, Kieseier B C, Hemmer B et al. Translational research in neurology and neuroscience 2010: Multiple sclerosis. Arch Neurol: 2010; 67 1307 1315
17. Winkelmann A, Loebermann M, Reisinger E C et al. Therapie der Multiplen Sklerose mit Fingolimod Infektiologische Aspekte und Hinweise zum Impfverhalten. Nervenarzt: 2010; 81 181 193
18. Loebermann M, Anders G, Brestrich G et al. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study. Vaccine: 2011; 29 1228 1234
19. Gilden D H. Infectious causes of multiple sclerosis. Lancet Neurol: 2005; 4 195 202 (Pubitemid 40269150)
20. Fernandez A M, PapaisAlvarenga M, Fernandez V et al. Microbes, immunity and multiple sclerosis. Curr Immunol Rev: 2011; 7 75 82
21. Stohlman S A, Hinton D R. Viral induced demyelination. Brain Pathol: 2001; 11 92 106
22. Ruprecht K. Multiple Sklerose und Epstein-Barr Virus: neue Entwicklungen und Perspektiven Nervenarzt: 2008; 79 399 407
23. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology: 2000; 11 220 224 (Pubitemid 30112026)
24. Levin L I, Munger K L, OReilly E J et al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol: 2010; 67 824 830
25. Alvarez-Lafuente R, Martin-Estefania C, de Las Heras V et al. Active human herpesvirus 6 infection in patients with multiple sclerosis. Arch Neurol: 2002; 59 929 933 (Pubitemid 34640752)
26. Enbom M. Human herpesvirus 6 in the pathogenesis of multiple sclerosis. APMIS: 2001; 109 401 411 (Pubitemid 32701844)
27. Altschuler E L. Is JC polyoma virus the cause of ulcerative colitis and multiple sclerosis? Med Hypotheses: 2000; 55 335 336
28. Dessau R B, Lisby G, Frederiksen J L. Coronaviruses in brain tissue from patients with multiple sclerosis. Acta Neuropathol: 2001; 101 601 604 (Pubitemid 32684759)
29. Kriesel J D, Sibley W A. The case for rhinoviruses in the pathogenesis of multiple sclerosis. Mult Scler: 2005; 11 1 4 (Pubitemid 40259967)
30. Perron H, Jouvin-Marche E, Michel M et al. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation. Virology: 2001; 287 321 332 (Pubitemid 32804018)
31. Rieger F, Pierig R, Cifuentes-Diaz C et al. New perspectives in multiple sclerosis: retroviral involvement and glial cell death. Pathol Biol (Paris): 2000; 48 15 24 (Pubitemid 30136674)
32. Rolland A, Jouvin-Marche E, Saresella M et al. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis. J Neuroimmunol: 2005; 160 195 203 (Pubitemid 40248609)
33. Bergstrom T. Herpesviruses a rationale for antiviral treatment in multiple sclerosis. Antiviral Res: 1999; 41 1 19 (Pubitemid 29132814)
34. Friedman J E, Zabriskie J B, Plank C et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler: 2005; 11 286 295 (Pubitemid 40775184)
35. Ramagopalan S V, Sadovnick A D. Epidemiology of Multiple Sclerosis. Neurologic Clinics: 2011; 29 207 217
36. Ascherio A, Munger K L. Epstein-barr virus infection and multiple sclerosis: A review. J Neuroimmune Pharmacol: 2010; 5 271 277
37. th MS Symposium held by the German Multiple Sclerosis Society. Nervenarzt: 2011; 82 1026 1035
38. Otto C, Oltmann A, Stein A et al. Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis. Neurology: 2011; 76 1316 1321
39. Simon K C, van der Mei I A, Munger K L et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology: 2010; 74 1365 1371
40. Sriram S, Stratton C W, Yao S et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol: 1999; 46 6 14 (Pubitemid 29314377)
41. Contini C, Cultrera R, Seraceni S et al. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler: 2004; 10 360 369 (Pubitemid 39117330)
42. Ebringer A, Hughes L, Rashid T et al. Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol: 2005; 62 33 36 (Pubitemid 40105033)
43. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature: 2004; 430 257 263 (Pubitemid 38902439)
44. Unterholzner L, Bowie A G. The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities. Biochem Pharmacol: 2008; 75 589 602
45. Gandhi R, Laroni A, Weiner H L. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol: 2010; 221 7 14
46. Carty M, Bowie A G. Evaluating the role of Toll-like receptors in diseases of the central nervous system. Biochem Pharmacol: 2011; 81 825 837
47. Ponsonby A L, van der Mei I, Dwyer T et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA: 2005; 293 463 469
48. Hernan M A, Alonso A, Hernandez-Diaz S. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology: 2006; 67 212 215 (Pubitemid 44305401)
49. Farez M F, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol: 2011;[Epub].
50. Buljevac D, Flach H Z, Hop W C et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain: 2002; 125 952 960 (Pubitemid 34464607)
51. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology: 2006; 67 652 659 (Pubitemid 44273613)
52. Tremlett H, van der Mei I A, Pittas F et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology: 2008; 31 271 279
53. Buljevac D, Verkooyen R P, Jacobs B C et al. Chlamydia pneumoniae and the Risk for Exacerbation in Multiple Sclerosis Patients. Ann Neurol: 2003; 54 828 831 (Pubitemid 37498967)
54. Ordoez G, Martinez-Palomo A, Corona T et al. Varicella zoster virus in progressive forms of multiple sclerosis. Clinical Neurology and Neurosurgery: 2010; 112 653 657
55. Pisa D, Alonso R, Carrasco L. Fungal infection in a patient with multiple sclerosis. Eur J Clin Microbiol Infect Dis. 2011;[Epub].
56. Chen X, Ma X, Jiang Y et al. The prospects of minocycline in multiple sclerosis. J Neuroimmunol: 2011; 235 1 8
57. Woessner R, Grauer M T, Frese A et al. Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis. Infection: 2006; 34 342 344 (Pubitemid 44968927)
58. Topkaya A E, Sahin S, Aksungar F B et al. Is there any relationship between streptococcal infection and multiple sclerosis? Med Sci Monit: 2007; 13 CR567 CR569 (Pubitemid 350272883)
59. Farrell R A, Antony D, Wall G R et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology: 2009; 73 32 38
60. Benito-Leon J, Pisa D, Alonso R et al. Association between multiple sclerosis and Candida species: evidence from a case-control study. Eur J Clin Microbiol Infect Dis: 2010; 29 1139 1145
61. Gea-Banacloche J C. Rituximab-associated infections. Semin Hematol: 2010; 47 187 198
62. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol: 2007; 61 97 108 (Pubitemid 46363837)
63. Edwards L J, Constantinescu C S. Parasite immunomodulation in autoimmune disease: Focus on multiple sclerosis. Exp Rev Clin Immunol: 2009; 5 487 489
64. Correale J, Farez M F. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol: 2011; 233 6 11
65. Aktas O, Kieseier B, Hartung H P. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci: 2010; 33 140 152
66. Abinun M. An overview of infectious complications in children on new biologic response-modifying agents. Pediatr Health: 2010; 4 509 517
67. Afif W, Loftus E V Jr. Safety profile of IBD therapeutics: infectious risks. Gastroenterol Clin North Am: 2009; 38 691 709
68. Breda L, Del Torto M, De Sanctis S et al. Biologics in childrens autoimmune disorders: efficacy and safety. Eur J Pediatr: 2011; 170 157 167
69. Berger J R, Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol: 2009; 65 367 377
70. Chinen J, Shearer W T. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol: 2010; 125 S195 S203
71. Leitlinienentwicklung Autorenportal der TMF zur Entwicklung klinischer Leitlinien S2 Leitlinie Multiple Sklerose: Diagnose und Therapie In: AWMF: 2011
72. Fensterl V, Sen G C. Interferons and viral infections. Biofactors: 2009; 35 14 20
73. Fridkis-Hareli M, Strominger J L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol: 1998; 160 4386 4397 (Pubitemid 28217296)
74. Ziemssen T, Kumpfel T, Klinkert W E et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain: 2002; 125 2381 2391 (Pubitemid 35303499)
75. Hong J, Li N, Zhang X et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA: 2005; 102 6449 6454 (Pubitemid 40617463)
76. Multiple Sklerose Therapie Konsensus Gruppe Rieckmann P. Escalating immunomodulatory therapy of multiple sclerosis. Update 2006. Nervenarzt: 2006; 77 1506 1518 (Pubitemid 44950149)
77. Multiple Sclerosis Therapy Consensus Group Wiendl H, Toyka K V et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol: 2008; 255 1449 1463
78. Cohen J A, Chun J. Mechanisms of fingolimods efficacy and adverse effects in multiple sclerosis. Ann Neurol: 2011; 69 759 777
79. Aktas O, Ingwersen J, Kieseier B et al. Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system. Nervenarzt: 2011; 82 215 225
80. Winkelmann A, Loebermann M, Reisinger E C et al. Fingolimod treatment for multiple sclerosis. What do we do with Varicella? In: Ann Neurol. 2011;(in press).
81. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol: 2008; 7 538 547 (Pubitemid 351657494)
82. Tony H P, Burmester G, Schulze-Koops H et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther: 2011; 13 R75
83. Leger O J, Yednock T A, Tanner L et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies: 1997; 8 3 16 (Pubitemid 27397156)
84. Warnke C, Menge T, Hartung H P et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol: 2010; 67 923 930
85. Clifford D B, De Luca A, Simpson D M et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol: 2010; 9 438 446
86. Brickelmaier M, Lugovskoy A, Kartikeyan R et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother: 2009; 53 1840 1849
87. Elphick G F, Querbes W, Jordan J A et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science: 2004; 306 1380 1383 (Pubitemid 39532516)
88. Cettomai D, McArthur J C. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol: 2009; 66 255 258
89. Schrder A, Lee D H, Hellwig K et al. Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol: 2010; 67 1391 1394
90. Warnke C, Adams O, Gold R et al. Progressive multifokale Leukenzephalopathie unter Natalizumab. Erste Mglichkeiten einer Risikostratifizierung? Nervenarzt: 2011; 82 475 480
91. Lanini S, Molloy A C, Fine P E et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med: 2011; 9 36
92. Carbone J, del Pozo N, Gallego A et al. Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev Anti Infect Ther: 2011; 9 405 413
93. Riminton D S, Hartung H P, Reddel S W. Managing the risks of immunosuppression. Curr Opin Neurol: 2011; 24 217 223
94. Awad A, Stuve O. Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms. Ther Adv Neurol Disord: 2009; 2 50 61
95. Marriott J J, Miyasaki J M, Gronseth G et al. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2010; 74 1463 1470
96. Rieckmann P, Toyka K V, Bassetti C et al. Escalating immunotherapy of multiple sclerosis new aspects and practical application. J Neurol: 2004; 251 1329 1339
97. Gold R, Stangel M, Dalakas M C. Drug Insight: the use of intravenous immunoglobulin in neurology therapeutic considerations and practical issues. Nat Clin Pract Neurol: 2007; 3 36 44 (Pubitemid 46056032)
98. Boschetti N, Stucki M, Spath P J et al. Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol: 2005; 29 333 344 (Pubitemid 43041686)
99. Weinshenker B G, OBrien P C, Petterson T M et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol: 1999; 46 878 886
100. Keegan M, Konig F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet: 2005; 366 579 582 (Pubitemid 41140333)
101. Weber M S, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta: 2011; 1812 239 245
102. Matzke B, Metze C, Winkelmann A et al. Severe relapse of multiple sclerosis during plasma exchange treatment. Mult Scler: 2011; 17 759 762
103. Zettl U K, Hartung H P, Pahnke A et al. Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology: 2006; 67 1515 1516 (Pubitemid 44632095)
104. Lehmann H C, Hartung H P, Hetzel G R et al. Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol: 2006; 63 930 935 (Pubitemid 44036291)
105. Wing E J, Bruns F J, Fraley D S et al. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA: 1980; 244 2423 2426 (Pubitemid 11232210)
106. Mokrzycki M H, Kaplan A A. Therapeutic plasma exchange: complications and management. Am J Kidney Dis: 1994; 23 817 827 (Pubitemid 24173565)
107. Haugh P J, Levy C S, Smith M A et al. Nosocomial Neisseria meningitidis sepsis as a complication of plasmapheresis. Clin Infect Dis: 1996; 22 1116 1117 (Pubitemid 26260631)
108. Vucic S, Davies L. Safety of plasmapheresis in the treatment of neurological disease. Aust N Z J Med: 1998; 28 301 305 (Pubitemid 28322353)
109. Kaneko S, Sata M, Ide T et al. Efficacy and safety of double filtration plasmapheresis in combination with interferon therapy for chronic hepatitis C. Hepatol Res: 2010; 40 1072 1081
110. Yeh J H, Chen W H, Chiu H C. Complications of double-filtration plasmapheresis. Transfusion: 2004; 44 1621 1625
111. Rodnitzky R L, Goeken J A. Complications of plasma exchange in neurological patients. Arch Neurol: 1982; 39 350 354 (Pubitemid 12109206)
112. Bouget J, Chevret S, Chastang C et al. Plasma exchange morbidity in Guillain-Barre syndrome: results from the French prospective, randomized, multicenter study. The French Cooperative Group. Crit Care Med: 1993; 21 651 658 (Pubitemid 23139541)
113. Boucher C A, de Gans J, van Oers R et al. Transmission of HIV and AIDS by plasmapheresis for Guillain-Barre syndrome. Clin Neurol Neurosurg: 1988; 90 235 236
114. Comenge Y, Girard M. Multiple sclerosis and hepatitis B vaccination: adding the credibility of molecular biology to an unusual level of clinical and epidemiological evidence. Med Hypotheses: 2006; 66 84 86 (Pubitemid 41605109)
115. Centers for Disease Control Prevention Adverse events associated with 17D-derived yellow fever vaccination United States, 20012002. MMWR Morb Mortal Wkly Rep: 2002; 51 989 993
116. Currier R D, Meydrech E F, Currier M M. Measles vaccination has had no effect on the occurrence of multiple sclerosis. Arch Neurol: 1996; 53 1216 (Pubitemid 26425065)
117. Ascherio A, Zhang S M, Hernan M A et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med: 2001; 344 327 332 (Pubitemid 32107640)
118. Confavreux C, Suissa S, Saddier P et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med: 2001; 344 319 326 (Pubitemid 32107639)
119. De Keyser J. Safety of tetanus vaccination in relapsing-remitting multiple sclerosis. Infection: 1998; 26 319 (Pubitemid 28466513)
120. De Keyser J, Zwanikken C, Boon M. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci: 1998; 159 51 53 (Pubitemid 28365883)
121. Uccelli A, Ginocchio F, Mancardi G L et al. Primary varicella zoster infection associated with fingolimod treatment. Neurology: 2011; 76 1023 1024
122. Sandrock A, Hotermans C, Richman S. Risk stratifikation for progressive multifocal leukencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Neurology: 2011; 76 P03.248